NICE recommends Sovaldi and Olysio for hepatitis C

25 February 2015

The UK’s National Institute for Health and Care Excellence (NICE) has published final guidance recommending hepatitis C drugs Sovaldi (sofosbuvir) from US biotech major Gilead Sciences (Nasdaq: GILD) and Olysio (simeprevir) from US health care giant Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen as treatment options for some people with chronic hepatitis C.

Sofosbuvir and simeprevir are oral antiviral drugs used to prevent hepatitis C viral replication in infected cells. The aims of treatment are to clear the virus from the blood to prevent progression of liver disease, and to prevent the transmission of the hepatitis C virus.

Sovaldi has marketing authorization in the UK for use in combination with other medicinal products for treating chronic hepatitis C in adults. The guidance on Sovaldi recommends its use in combination with ribavirin, with or without peginterferon alfa, as an option for some people with genotypes 1- 6 chronic hepatitis C.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK